Pfizer Inc. said that it will invest about $350 million to build a global biotechnology center in China. The facility – Pfizer’s first biotechnology center in Asia – will be built in the Hangzhou Economic Development Area in China. The Pfizer Global … [Read more...]
Pfizer Inc. (NYSE:PFE) Acquires Anacor for $5 Bn, is Amgen Next?
Pfizer Inc. (NYSE:PFE) has said that it has completed the process of acquiring Anacor Pharmaceuticals, Inc. As per the firm, the transaction terms provided each outstanding share of Anacor to be converted into the right to get $99.25 net in cash, … [Read more...]
Inovio Pharmaceuticals Inc (INO) Soared Nearly 7% Monday; Here’s Why
Shares of Inovio Pharmaceuticals Inc surged 6.97% Monday after the company announced that regulators approved its application to start an early stage human trial to test its Zika vaccine. Zika virus disease is caused by a virus transmitted primarily … [Read more...]
FDA Says Pfizer Inc (PFE)’s Troxyca ER Might be Abused By Opioid Addicts
Pfizer Inc. was in the news on Monday after a preliminary review by the U.S Food and Drug Administration revealed that opioid addicts might find ways to abuse its experimental extended release opioid painkiller. Pfizer has previously made a filing … [Read more...]
Here’s Why Celator Pharmaceuticals Inc (NASDAQ:CPXX) Up Over 70% Today
Celator Pharmaceuticals Inc has agreed to be acquired by Jazz Pharmaceuticals plc - Ordinary Shares for $30.25 per share or about $1.5 billion in cash. Jazz believes that the acquisition will help the company to advance its growth strategy. Shares … [Read more...]
Ionis Pharmaceuticals Inc (IONS) Got Killed Yesterday: Here’s Why
Shares of Ionis Pharmaceuticals Inc are trading in red after the company announced that GlaxoSmithKline plc (ADR) , which has an option to exclusively license IONIS-TTR Rx, will not initiate the phase 3 study, CARDIO-TTR. The study, designed to … [Read more...]
Pfizer Inc. (NYSE:PFE) Near-Term M&A Strategy: Build The Oncology Portfolio
Pfizer Inc. believes the markets are yet to give it full credit for its efforts to stay ahead in cancer therapy. Pfizer’s President Liz Barrett says the company has a broad oncology portfolio that is largely ignored. Ms. Barrett made the comments on … [Read more...]
Pfizer Inc. (NYSE:PFE) Unveils Noteable Progress in Cancer Research
Pfizer Inc. said that the firm will have its largest presence to date at the 52nd annual meeting of the American Society of Clinical Oncology (ASCO). This will take place in Chicago from June 3-7. It will have more than 40 abstracts spanning a … [Read more...]
Pfizer Inc. (NYSE:PFE) Aiming For Cost Savings and Product Development
Pfizer Inc. (NYSE:PFE) is looking for ways to reach $1 bn of Hospira cost savings by 2018. Hospira is a maker of injectable drugs and infusion devices. During the course of its Q1 2016 earnings release, the firm added that for the remainder of 2016, … [Read more...]
Another Setback for Pfizer Inc. (PFE) as R&D Exec Moves to Biogen
Pfizer Inc. held its annual meeting of shareholders on Thursday. Ian Read, chairman and CEO of the firm said that they remain focused on strengthening the two main divisions, i.e. innovative and established businesses. They will also strive to … [Read more...]